Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on Osimertinib PK in EGFRm+ NSCLC
NCT02197247Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 49 and Area Under the Plasma Concentration-time Curve During the Dosing Interval at Day 49. Started Dec 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02197247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02197247.